Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Unii-4mod1f4enc
2. Ko539
3. Ko-539
4. 4mod1f4enc
5. 2134675-36-6
6. Menin-mll Interaction Inhibitor Ko 539
7. (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile
8. 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2s)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
9. Ziftomenib [usan]
10. Ko-539;ziftomenibum
11. Ziftomenib [inn]
12. Ko 539 [who-dd]
13. Schembl20846943
14. Gtpl11680
15. Ex-a5611
16. Who 11651
17. Compound 151 [us10781218b2]
18. Hy-132001
19. Cs-0146342
20. 1h-indole-2-carbonitrile, 4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)-1-piperidinyl)methyl)-1-((2s)-2-(4-(methylsulfonyl)-1-piperazinyl)propyl)-
| Molecular Weight | 717.9 g/mol |
|---|---|
| Molecular Formula | C33H42F3N9O2S2 |
| XLogP3 | 5.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 10 |
| Exact Mass | 717.28549845 g/mol |
| Monoisotopic Mass | 717.28549845 g/mol |
| Topological Polar Surface Area | 159 Ų |
| Heavy Atom Count | 49 |
| Formal Charge | 0 |
| Complexity | 1270 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Ziftomenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ziftomenib, including repackagers and relabelers. The FDA regulates Ziftomenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ziftomenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ziftomenib supplier is an individual or a company that provides Ziftomenib active pharmaceutical ingredient (API) or Ziftomenib finished formulations upon request. The Ziftomenib suppliers may include Ziftomenib API manufacturers, exporters, distributors and traders.
Ziftomenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ziftomenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ziftomenib GMP manufacturer or Ziftomenib GMP API supplier for your needs.
A Ziftomenib CoA (Certificate of Analysis) is a formal document that attests to Ziftomenib's compliance with Ziftomenib specifications and serves as a tool for batch-level quality control.
Ziftomenib CoA mostly includes findings from lab analyses of a specific batch. For each Ziftomenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ziftomenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ziftomenib EP), Ziftomenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ziftomenib USP).
LOOKING FOR A SUPPLIER?
